CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH Illuminating the Path: Novel Fluorescence Imaging Agent Revolutionizes Prostate Cancer Detection
In a study led by UCSF researchers, the novel near-infrared fluorescence imaging agent IS-002 has demonstrated significant potential in enhancing the detection of prostate cancer during surgery. This first-in-human study marks a pivotal advancement in prostate cancer care, offering a new avenue for surgeons to identify and remove cancerous tissues that are undetectable through conventional imaging methods.
Key Points:
- UCSF researchers conducted the first-in-human study of IS-002, a near-infrared fluorescence imaging agent targeting PSMA, showing promise for intraoperative detection of prostate cancer.
- IS-002 specifically binds to the PSMA receptor, potentially improving the precision of prostatectomy outcomes.
- In a phase 1 study involving 24 high-risk prostate cancer patients, IS-002 enabled the detection of cancerous tissues not visible with standard white light imaging.
- The agent was found to be safe, rapidly cleared from the body, and allowed real-time visualization of prostate cancer.
- Twelve patients had previously undetected disease identified, with locoregional or residual disease found in the prostate resection bed of seven patients and metastatic lymph nodes identified in five patients.
- The efficacy of IS-002 highlights its potential to facilitate more complete cancer excision and minimize morbidity.
- A multisite, randomized phase 2 trial of IS-002 is currently underway at UCSF.
- PSMA PET, a related imaging modality also pioneered by UCSF researchers, has already impacted cancer staging and treatment planning due to its heightened sensitivity.
- The integration of IS-002 fluorescence imaging with robotic-assisted surgery represents a significant technological advance in real-time disease identification.
“We’re using advanced technology to better identify disease in real time and manage the patient’s cancer based on the imaging. The fluorescent camera is built into the robot, so this technology can be rapidly deployed.”
– Peter Carroll, MD, MPH, UCSF Urologic Cancer Surgeon
More in Urology
